Current Status and Future Role of Brain PET/MRI in Clinical and Research Settings

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2015 Jan 10

PMID 25573629

Citations 25

Authors

P Werner

H Barthel

A Drzezga

O Sabri

Affiliations

Soon will be listed here.

Abstract

Hybrid PET/MRI systematically offers a complementary combination of two modalities that has often proven itself superior to the single modality approach in the diagnostic work-up of many neurological and psychiatric diseases. Emerging PET tracers, technical advances in multiparametric MRI and obvious workflow advantages may lead to a significant improvement in the diagnosis of dementia disorders, neurooncological diseases, epilepsy and neurovascular diseases using PET/MRI. Moreover, simultaneous PET/MRI is well suited to complex studies of brain function in which fast fluctuations of brain signals (e.g. related to task processing or in response to pharmacological interventions) need to be monitored on multiple levels. Initial simultaneous studies have already demonstrated that these complementary measures of brain function can provide new insights into the functional and structural organization of the brain.

Citing Articles

Peak width of skeletonized mean diffusivity: a novel biomarker for white matter damage in spinocerebellar ataxia type 2.

Chen N, Peng J, Xiong F, Tu Y Neuroradiology. 2024; 67(1):183-189.

PMID: 39535589 DOI: 10.1007/s00234-024-03499-5.

PET-MRI Applications and Future Prospects in Psychiatry.

Zurcher N, Chen J, Wey H J Magn Reson Imaging. 2024; 61(2):568-578.

PMID: 38838352 PMC: 11617601. DOI: 10.1002/jmri.29471.

Application of Deep Learning for Prediction of Alzheimer's Disease in PET/MR Imaging.

Zhao Y, Guo Q, Zhang Y, Zheng J, Yang Y, Du X Bioengineering (Basel). 2023; 10(10).

PMID: 37892850 PMC: 10604050. DOI: 10.3390/bioengineering10101120.

Study on the radiofrequency transparency of partial-ring oval-shaped prototype PET inserts in a 3 T clinical MRI system.

Akram M, Levin C, Nishikido F, Takyu S, Obata T, Yamaya T Radiol Phys Technol. 2023; 17(1):60-70.

PMID: 37874462 DOI: 10.1007/s12194-023-00747-w.

Hybrid PET/MRI in Cerebral Glioma: Current Status and Perspectives.

Langen K, Galldiks N, Mauler J, Kocher M, Filss C, Stoffels G Cancers (Basel). 2023; 15(14).

PMID: 37509252 PMC: 10377176. DOI: 10.3390/cancers15143577.

References

Delso G, Furst S, Jakoby B, Ladebeck R, Ganter C, Nekolla S . Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner. J Nucl Med. 2011; 52(12):1914-22. DOI: 10.2967/jnumed.111.092726. View

Werner P, Fritzsch D, Holland H, Bauer M, Krupp W, Hoffmann K . Definition of primary and secondary glioblastoma--letter. Clin Cancer Res. 2014; 20(7):2011-2. DOI: 10.1158/1078-0432.CCR-13-3190. View

Lee K, Salamon N . [18F] fluorodeoxyglucose-positron-emission tomography and MR imaging coregistration for presurgical evaluation of medically refractory epilepsy. AJNR Am J Neuroradiol. 2009; 30(10):1811-6. PMC: 7051291. DOI: 10.3174/ajnr.A1637. View

Rezaei A, Defrise M, Nuyts J . ML-reconstruction for TOF-PET with simultaneous estimation of the attenuation factors. IEEE Trans Med Imaging. 2014; 33(7):1563-72. DOI: 10.1109/TMI.2014.2318175. View

Purz S, Sabri O, Viehweger A, Barthel H, Kluge R, Sorge I . Potential Pediatric Applications of PET/MR. J Nucl Med. 2014; 55(Supplement 2):32S-39S. DOI: 10.2967/jnumed.113.129304. View

Pirotte B, Goldman S, Massager N, David P, Wikler D, Vandesteene A . Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med. 2004; 45(8):1293-8. View

Navalpakkam B, Braun H, Kuwert T, Quick H . Magnetic resonance-based attenuation correction for PET/MR hybrid imaging using continuous valued attenuation maps. Invest Radiol. 2013; 48(5):323-32. DOI: 10.1097/RLI.0b013e318283292f. View

Popperl G, Kreth F, Mehrkens J, Herms J, Seelos K, Koch W . FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging. 2007; 34(12):1933-42. DOI: 10.1007/s00259-007-0534-y. View

Galldiks N, Ullrich R, Schroeter M, Fink G, Jacobs A, Kracht L . Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme. Eur J Nucl Med Mol Imaging. 2009; 37(1):84-92. PMC: 2791473. DOI: 10.1007/s00259-009-1219-5. View

10.

Olivot J, Mlynash M, Thijs V, Kemp S, Lansberg M, Wechsler L . Optimal Tmax threshold for predicting penumbral tissue in acute stroke. Stroke. 2008; 40(2):469-75. PMC: 2670783. DOI: 10.1161/STROKEAHA.108.526954. View

11.

Kendziorra K, Wolf H, Meyer P, Barthel H, Hesse S, Becker G . Decreased cerebral α4β2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography. Eur J Nucl Med Mol Imaging. 2010; 38(3):515-25. DOI: 10.1007/s00259-010-1644-5. View

12.

Schultz C, Fusar-Poli P, Wagner G, Koch K, Schachtzabel C, Gruber O . Multimodal functional and structural imaging investigations in psychosis research. Eur Arch Psychiatry Clin Neurosci. 2012; 262 Suppl 2:S97-106. DOI: 10.1007/s00406-012-0360-5. View

13.

Su Y, Arbelaez A, Benzinger T, Snyder A, Vlassenko A, Mintun M . Noninvasive estimation of the arterial input function in positron emission tomography imaging of cerebral blood flow. J Cereb Blood Flow Metab. 2012; 33(1):115-21. PMC: 3597366. DOI: 10.1038/jcbfm.2012.143. View

14.

Alsop D, Dai W, Grossman M, Detre J . Arterial spin labeling blood flow MRI: its role in the early characterization of Alzheimer's disease. J Alzheimers Dis. 2010; 20(3):871-80. PMC: 3643892. DOI: 10.3233/JAD-2010-091699. View

15.

Fougere C, Suchorska B, Bartenstein P, Kreth F, Tonn J . Molecular imaging of gliomas with PET: opportunities and limitations. Neuro Oncol. 2011; 13(8):806-19. PMC: 3145468. DOI: 10.1093/neuonc/nor054. View

16.

Jagust W . Time for tau. Brain. 2014; 137(Pt 6):1570-1. DOI: 10.1093/brain/awu093. View

17.

Barthel H, Gertz H, Dresel S, Peters O, Bartenstein P, Buerger K . Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011; 10(5):424-35. DOI: 10.1016/S1474-4422(11)70077-1. View

18.

Merino J, Warach S . Imaging of acute stroke. Nat Rev Neurol. 2010; 6(10):560-71. DOI: 10.1038/nrneurol.2010.129. View

19.

Keereman V, Fierens Y, Broux T, De Deene Y, Lonneux M, Vandenberghe S . MRI-based attenuation correction for PET/MRI using ultrashort echo time sequences. J Nucl Med. 2010; 51(5):812-8. DOI: 10.2967/jnumed.109.065425. View

20.

Purz S, Mauz-Korholz C, Korholz D, Hasenclever D, Krausse A, Sorge I . [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma. J Clin Oncol. 2011; 29(26):3523-8. DOI: 10.1200/JCO.2010.32.4996. View